Concepts of Antibody-Mediated Cancer Therapy

References

• Davies D R, Metzger H. Structural basis of antibody iunction. Annu Rev Immunol 1983; 1: 87–121
   PubMed Web of Science ®Google Scholar
• Bernstein I D, Nowinski R C, Tam M, Mc R., Master B, Houston L L, Clark E A. Monoclonal antibody therapy of mouse leukemia. Monoclonal Antibodies, Kennet, McKearn, Bechtol. Plenum Press, New York 1980; 275
   Google Scholar
• Hale G, Clark M, Waldmann H. Therapeutic potential of rat monoclonal antibodies: lsotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Inimunol 1985; 134: 3056–3061
   PubMed Web of Science ®Google Scholar
• Cheung N-K, Lazams H, Miraldi F D, Abramowsky C R, Kallick S, Saarinen U M, Spitzer T, Strandjord S E, Coccia PF., Berger N A. Ganglioside GD? specific monoclonal antibody 3F8: A phase I study in patients with melanoma and neuroblastonia. J Clin Oncol 1987; 5: 1430–1440
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton M A, Oettgen H F, Old L J, Houghton A N. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: Induction of intlammatory responses at tumor sites. J Clin Oncol 1988; 6: 1636–1648
   PubMed Web of Science ®Google Scholar
• Hale G, Dyer M JS, Clark M J, Phillips J M, Marcuh R, Riech-mann L, Winter G, Waldmann H. Remission induction in non-Hodgkin lymphoma with the reshaped human monoclonal antibody CAMPATH-IH. Lancet 1988; 2: 1394–1399
   PubMed Web of Science ®Google Scholar
• Kummer U, Thierfelder S, Hoffmann-Fezer G, Schuh R. In vivo immunosuppression by pan-T-cell antibodies relates to their isotype and to their Clq uptake. J Immunol 1987; 138: 4069–4075
   PubMed Web of Science ®Google Scholar
• Kummer U, Thierfelder S, Mysliwietz J. Antigen density on target cells determines the immunosuppressive potential of rat IgG2b monoclonal antibodies. Eur J Immunol 1990; 20: 107–112
   PubMed Web of Science ®Google Scholar
• Sorvillo J, Gigli I, Pearlstein E. Fibronectin binding to Clq associated with antigen-antibody complexes in EDTA-treated plasma. Scand J Immunol 1986; 23: 153–160
   PubMed Web of Science ®Google Scholar
• Ehlenberger A G, Nussenzweig V. The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med 1977; 145: 357–371
   PubMed Web of Science ®Google Scholar
• Opitz H G, Opitz U, Hewelett G, Schluniberger H D. A new model for investigation of T-cell functions in mice: Differential immunosuppressive effects of two monoclonal anti-Thy-1.2 antibodies. Immunobiology 1980; 160: 438–453
   Web of Science ®Google Scholar
• Cobbold S P, Thierfelder S, Waldmann H. Immunosuppression with monoclonal antibodies: A model to determine the rules tor effective serotherapy. Mol Biol Med 1983; 1: 285–304
   PubMedGoogle Scholar
• Kinoshita T, Medof M E, Nussenzweig V. Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes. J Immunol 1986; 136: 3390
   PubMed Web of Science ®Google Scholar
• Fujita T, Lnoue T, Ogawa K, Tamura N. The mechanism of action of decay-accelerating factor (DAF): DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med 1987; 166: 1221
   PubMed Web of Science ®Google Scholar
• Cheung N-K, El Walter, Smith-Mensah W H. Decay-ating factor protects human tumor cells from coniplement-niediated cytotoxicity in vitro. J Clin Invest 1988; 81: 1122
   PubMed Web of Science ®Google Scholar
• Morgan E L, Weigle W O. Biological activities residing in the Fc region of immunoglobulin. Adv Immunol 1987; 40: 61–133
   PubMed Web of Science ®Google Scholar
• Hogg N. The structure and function of Fc receptors. Immunol Today 1988; 9: 185–187
   PubMedGoogle Scholar
• Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA 1982; 79: 4761–4765
   PubMed Web of Science ®Google Scholar
• Seto M, Takahashi T, Nakamura S, Matsudaira Y, Nishizuka Y. In vivo tumor effects of monoclonal antibodies with different immunoglobulin classes. Cancer Res 1983; 43: 4768–4773
   PubMed Web of Science ®Google Scholar
• Lanier L L, Phillips J H. Evidence of three types of human cy-totoxic lymphocytes. lmmunol Today 1986; 7: 132–134
   PubMedGoogle Scholar
• Ralph P, Nakoinz I. Cell-mediated lysis of tumor targets directed by murine monoclonal antibodies of IgM and all IgG isotypes. J lmmunol 1983; 131: 1028–1031
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Kitamura K, Maloney D G, Campabell M, Levy J. R. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol 1986; 136: 1123–1130
   PubMed Web of Science ®Google Scholar
• Steplewski Z, Lubeck M D, Koprowski H. Human macrophages armed with murine immunoglobulin IgG2a antibodies to tumors destroy human cancer cells. Science 1983; 221: 865–867
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Hellstrom K E, Yeh M. Lymphocyte-dependent antibodies to antigen 3.1. A cell-surface antigen expressed by a subgroup of human melanomas. Int J Cancer 1981; 27: 281–285
   PubMed Web of Science ®Google Scholar
• Imai K, Pellegrino M A, Wilson B S, Ferrone S. Higher cytolytic efficiency of an IgG2a than of an IgGI monoclonal antibody reacting with the same (or spatially close) determinant on a human high-molecular-weight melanoma-associated antigen. Cell Immunol 1982; 72: 239–247
   PubMed Web of Science ®Google Scholar
• Kipps T J, Parham P, Punt J, Herzenberg L A. Importance of immunoglobulin isotype in human antibody-dependent cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med 1985; 161: 1–17
   PubMed Web of Science ®Google Scholar
• Koehler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–498
   PubMed Web of Science ®Google Scholar
• Tramontano A, Janda K D, Lerner R A. Catalytic antibodies. Science 1986; 234: 1566–1569
   PubMed Web of Science ®Google Scholar
• Pollack S J, Jacobs J W, Schultz P G. Selective chemical catalysis by an antibody. Science 1986; 256: 1570–1573
   Google Scholar
• Jones P T, Dear P H, Foote J, Neuberger M S, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321: 522–524
   PubMed Web of Science ®Google Scholar
• Neuberger M S, Williams G T, Mitchell E B, Joukal S S, Flanagan J G, Rabbitts T H. A hapten-specific chimeric IgE antibody with human physiological effector function. Nature 1985; 314: 268–270
   PubMed Web of Science ®Google Scholar
• Duncan A R, Winter G. The binding site of Clq on IgG. Nature 1988; 332: 738–740
   PubMed Web of Science ®Google Scholar
• Brueggeman M, Williams G T, Binder C I, Clark M R, Walker MP, Jeffrey R, Waldmann H, Neuberger M S. Comparison of the effector functions of human immunoglobulin using a matched set of chimeric antibodies. J Exp Med 1987; 166: 1351–1361
   PubMed Web of Science ®Google Scholar
• Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323–327
   PubMed Web of Science ®Google Scholar
• Van der Zee J S, Van Swieten P, Aalberse R C. Inhibition of complement activation by IgG4 antibodies. Clin Exp lmmunol 1986; 64: 415–422
   PubMed Web of Science ®Google Scholar
• LoBuglio A F, Wheeler R O, Troy J, Haynes B, Harvey E B, Sun L, Ghrayeb J, Khazaeli M B. Mouse/human chimeric monoclonal antibodies in man: Kinetics and immune response. Proc Natl Acad Sci USA 1989; 86: 4220–4224
   PubMed Web of Science ®Google Scholar
• Brueggemann M, Winter G, Waldmann H, Neuberger M S. The immunogenicity of chimeric antibodies. J Exp Med 1989; 170: 2153–2157
   PubMed Web of Science ®Google Scholar
• Verhoeyen M, Milstein C, Winter G. Reshaping human antibodies: Grafting an anti-lysozyme activity. Science 1988; 239: 1534–1536
   PubMed Web of Science ®Google Scholar
• Queen C, Schneider W P, Selick H E, Payne P W, Landolfi N F, Duncan J F, Avdalovic N M, Levill M, Junghans R F, Waldmann T. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989; 86: 10029–10033
   PubMed Web of Science ®Google Scholar
• Junghans R P, Waldmann T A, Landolfi N F, Avdalovic N M, Schneider W P, Queen C. Anti-Tac-H a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990; 50: 1495–1502
   PubMed Web of Science ®Google Scholar
• Saga T, Endo M, Koizumi M, Kawamura Y, Watanabe Y, Ko-nishi J, Ueda R, Nishimura Y, Yokoyama M, Watanabe T. In vitro and in vivo properties of humanimouse chimeric monoclonal antibodies specific for common acute lymphocytic leukemia antigen. J Nucl Med 1990; 31: 1077–1083
   PubMed Web of Science ®Google Scholar
• Stevenson F K, Bell A J, Cusack R, Hamblin T J, Slade C J, Spellerberg M B, Stevenson G T. Preliminary studies for an im-munotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 1991; 77: 1071–1079
   PubMed Web of Science ®Google Scholar
• Knox S J, Levy R, Hodgkinson S, Bell R, Brown S, Wood G S, Hoppe R, Abel E A, Steinman L, Berger R G. Observations on the effect of chimeric anti-CD4 monoclonal antibodies in patients with mycosis fungoides. Blood 1991; 77: 20–30
   PubMed Web of Science ®Google Scholar
• Brown S L, Miller R A, Levy R. Antiidiotype antibody therapy of B cell lymphoma. Semin Oncol 1989; 16: 199–210
   PubMed Web of Science ®Google Scholar
• Khazaeli M B, Saleh M N, Liu T P, Meredith R F, Wheeler R H, Baker T S, King D, Secher D, Allen L, Rogers K, Colcher D, Schlom J, Shochat D, LoBuglio A F. Pharmacokinetics and immune response of 131I-chimeric mouse/human 872.3 (human gamma 4) monoclonal antibody in humans. Cancer Res 1991; 51: 5461–5466
   PubMed Web of Science ®Google Scholar
• Chaudhary V K, Queen C, Junghans R F, Waldmann T, Fitzgerald D J, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989; 339: 393–394
   Google Scholar
• Neuberger M S, Williams G T, Fox R O. Recombinant antibodies possessing novel effector functions. Nature 1984; 312: 604–608
   PubMed Web of Science ®Google Scholar
• Saul F A, Amzel L M, Poljak R J. Preliminary refinement and structural analysis of the Fab fragment form human immunoglobulin new at 2.0A resolution. J Biol Chem 1978; 253: 585–597
   PubMed Web of Science ®Google Scholar
• Boulot G, Eisele J-L, Bentley G A, Bhat T N, Ward E S, Winter G, Poljak R J. Crystallization and preliminary X-ray diffraction study of the bacterially expressed Fv from the monoclonal anti-lysozyme antibody DI.3 and its complex with the antigen ly-sozyme. J Mol Biol 1990; 213: 617–619
   PubMed Web of Science ®Google Scholar
• Riechmann L, Foote J, Winter G. Expression of an antibody Fv fragment in myeloma cells. J Mol Biol 1988; 203: 5325–828
   Google Scholar
• Winter G, Milstein C. Man-made antibodies. Nature 1991; 349: 293–299
   PubMed Web of Science ®Google Scholar
• Roder J C, Cole S PC, Kozbor D. The EBV-hybridoma technique. Methods Enzymol 1986; 121: 140–167
   PubMed Web of Science ®Google Scholar
• Vitetta E S, Uhr J W. Immunotoxins. Annu Rev Immunol 1985; 3: 197–212
   PubMed Web of Science ®Google Scholar
• Yamaizumi M, Mekado E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill a cell. Cell 1978; 15: 245–250
   PubMed Web of Science ®Google Scholar
• Van Ness B G, Howard J B, Brodley J W. ADP-ribosylation of elongation factor 2 by diphtheria toxin. NMR spectra and proposed structure of ribosyldiphthamide and its hydrolysis products. J Biol Chem 1980; 255: 10710–10716
   PubMed Web of Science ®Google Scholar
• Nolan R D, Grdsmuk H, Drews J. The binding of tritiated elongation factors 1 and 2 to ribosomes from Krebs II mouse acites tumor cells. The influence of various antibotics toxins. Eur J Biochem 1976; 64: 69–75
   PubMedGoogle Scholar
• Endo Y, Misui K, Motizuki M, Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and characteristics of the modification in 28S ribosomal RNA caused by the toxin. J Biol Chem 1986; 262: 5908–5912
   Web of Science ®Google Scholar
• Stirpe F, Olsnes S, Pihl A. Gelonin, a new inhibitor of protein synthesis. non-toxic to intact cells. Isolation. characterization and preparation of cytotoxic complexes with concanavalin A. J Biol Chem 1980; 255: 6947–6953
   PubMed Web of Science ®Google Scholar
• Barbieri L, Zdmboni M, Lorezoni E, Montanero L, Sperti S, Stirpe F. Inhibition of protein synthesis in vitro by proteins from the seeds of Monocardia charantia (bitter pear melon). Biochem J 1980; 186: 443–452
   PubMed Web of Science ®Google Scholar
• Moolten F L, Cooperband S R. Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science 1970; 169: 58–70
   Google Scholar
• Thorpe P E, Ross W CJ, Cumber A J, Hinson C A, Edwards D C, Davies A JS. Toxicity of diphtheria toxin for human lympho-blastoid cells is increased by conjugation to anti-lymphocytic globulin. Nature 1978; 272: 752–755
   Google Scholar
• Masuho Y, Hara T, Teruhiso N. Preparation of a hybrid fragment Fab of antibody and fragment A of diphtheria toxin and its cytotoxicity. Biochem Biophys Res Commun 1976; 90: 320–326
   Google Scholar
• Ramakrishnan S, Houston L L. Inhibition of human acute lym-phoblastic leukemia cells by immunotoxins: Potentiation by chloroquine. Science 1984; 223: 58–61
   PubMed Web of Science ®Google Scholar
• Fulton R J, Uhr J W, Vitetta E S. The effect of antibody valency and lysomotropic amines on the synergy between ricin A chain-and ricin B chain-containing immunotoxins. J Immunol 1986; 136: 3103–3109
   PubMed Web of Science ®Google Scholar
• Skilleter D N, Foxwell B MJ. Selective uptake of ricin A-chain by hepatic non-parenchymal cells in vitro. Importance of man-nose oligosaccharides in the toxin. FEBS Lett 1986; 196: 344–348
   PubMed Web of Science ®Google Scholar
• Blakey D C, Thorpe P E. Effect of chemical deglycosylation on the in vivo fate of ricin A-chain. Cancer Drug Deliv 1986; 3: 189–196
   PubMedGoogle Scholar
• Thorpe P E, Blakey D C, Brown A NF, Knowles P P, Knyba R E, Wallace P M, Watson G J. Comparison of two anti-Thyl-1-ricin A chain immunotoxins prepared with different cross-linking agents: Anti-tumor effects, in vivo fate and tumor cell mutants. J Natl Cancer Inst 1987; 79: 1101–1111
   PubMed Web of Science ®Google Scholar
• Moolten F L, Capparell N J, Zajdel S H, Cooperband S R. Anti-tumor effects of antibody-diphtheria toxin conjugates. II. Im-munotherapy with conjugates directed against tumor antigens induced by simian virus 40. J Natl Cancer Inst 1975; 55: 473–477
   PubMed Web of Science ®Google Scholar
• Krolick K A, Uhr J W, Slavin S, Vitetta E S. In vivo therapy of a murine B cell tumor (BCLI) using antibody-rich A-chain immunotoxins. J Exp Med 1982; 155: 1797–1809
   PubMed Web of Science ®Google Scholar
• Bernhard M I, Foon K A, Oeltmann T N, Key M E, Hwang K M, Clarke G C, Christensen W L, Hoyer L C, Hanna MG, Jr, Oldhani R K. Guinea pig line L10 hepatocarcinoma model: Characterisation of monoclonal antibody and in vivo effect of unconju-gated antibody and antibody conjugated to diphtheria toxin A-chain. Cancer Res 1983; 43: 4420–4428
   PubMed Web of Science ®Google Scholar
• Vallera D A, Ash R C, Zanjani E D, Kersey J H, LeBien J W, Beverley P CL, Neville D M, Jr., Youle R J. Anti-T cell reagents for human bone marrow transplantation: Ricine linked to three monoclonal antibodies. Science 1983; 222: 572–575
   Google Scholar
• Filipovich A H, Vallera D A, Youle R J, Quinones R R, Neville D M, Jr., Kersey J H. Ex-vivo treatment of donor bone marrow with anti-T cell imrnunotoxins for prevention of graft-versus-host disease. Lancet 1984; 1: 469–472
   PubMed Web of Science ®Google Scholar
• Muirhead M, Martin P J, Torok-Storb B, Uhr J W, Vitetta E S. Use of an antibody-ricin A chain conjugate to delete neoplasticB cells from human bone marrow. Blood 1983; 62: 327–332
   PubMed Web of Science ®Google Scholar
• Krolick K A, Yuan D, Vitetta E S. Specific killing of a human breast carcinoma cell line by a monoclonal antibody coupled to the A-chain of ricin. Cancer Immunol Immunother 1981; 12: 39–41
   Web of Science ®Google Scholar
• Coombes R C, Buckman R, Forrester J A, Shepherd V, O'Hare M J, Vincent M, Powles T J, Neville A M. In vitro and in vivo effects of a monoclonal antibody-toxin conjugate for the use in autologous bone marrow transplantation for patients with breast cancer. Cancer Res 1986; 46: 4217–4220
   PubMed Web of Science ®Google Scholar
• Laurent G, Pris J, Farcet J P, Carayon P, Blythrnan C, Casellas P, Poncelet P, Jansen F K. Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood 1986; 67: 1680–1687
   PubMed Web of Science ®Google Scholar
• Spiler L E, De Rio M, Khentigan A, Wedel N I, Brophy N A, Miller L L, Harkonen W S, Rosedorf L L, Lee H M, Mishak K P, Kawahata R I, Stoudemire J B, Fradkin L B, Bautista E E, Scan-non P J. Therapy of patients with malignant melanoma. using a monoclonal melanoma antibody-ricin A chain immunotoxin. Cancer Res 1987; 47: 1717–1733
   PubMed Web of Science ®Google Scholar
• Hammerling U, Aoki T, DeHarven E, Boyse E A, Old L J. Use of hybrid antibody with anti-gamma-G and anti-ferritin speeificities in locating cell surface antigens by electron microscopy. J Exp Med 1968; 128: 1461–1473
   PubMed Web of Science ®Google Scholar
• Staerz U D, Bevan M J. Hybrid hybridoma producins a bispecific monoclonal antibody which can focus effector T cell activity. Proc Natl Acad Sci USA 1986; 83: 1453–1457
   PubMed Web of Science ®Google Scholar
• Cotton R GH, Milstein C. Fusion of two immunoglobulin-pro-ducing cell lines. Nature 1973; 244: 42–43
   PubMed Web of Science ®Google Scholar
• Koehler G, Howe S C, Milstein C. Fusion between immuno-globulin secreting and non-secreting myeloma cell lines. Eur J Immunol 1976; 6: 292–295
   PubMed Web of Science ®Google Scholar
• Karawajew L, Micheel B, Behrsing O, Gaestel M. Bispecific antibody-producing hybrid hybridomas sclcctcd by a tluorescence activated cell sorter. J Immunol Methods 1987; 96: 265–270
   PubMed Web of Science ®Google Scholar
• Wright W E. The isolation of hcterokaryons and hybrids by a selective system using irreversible biochemical inhibitors. Exp Cell Res 1978; 112: 395–407
   PubMed Web of Science ®Google Scholar
• Milstein C, Cuello A C. Hybrid hybridomas and their use in immunochemistry. Nature 1983; 305: 537–540
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 1985; 6: 292–295
   Google Scholar
• Staerz U D, Kanagawa O, Bevan M J. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314: 628–631
   PubMed Web of Science ®Google Scholar
• Bode C, Runge M S, Branscomb E E, Newell J B, Matsueda G R, Habe E. Antibody-directed fibrinolysis; an antibody specific for both fibrin and tissue plasminogen activator. J Biol Chem 1989; 264: 944–948
   PubMed Web of Science ®Google Scholar
• Hoffman R W, Bluestone J A, Leo O, Shaw S. Lysis of anti-T3 bearing murine hybridoma cells by human allospecific cytotoxic T cell clones and inhibition of that lysis by anti-T3 and anti-LFA-1 antibodies. J Immunol 1985; 135: 5–8
   PubMed Web of Science ®Google Scholar
• Kranz D M, Tonegawa S, Eisen H. Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T Iymphocytes. Proc Natl Acad Sci USA 1984; 81: 7922–7926
   PubMed Web of Science ®Google Scholar
• Staerz U D, Bevan M J. Cytotoxic T Iymphocyte mediated lysis via the Fc receptor of target cells. Eur J Immunol 1985; 15: 1172–1177
   PubMed Web of Science ®Google Scholar
• Staerz U D, Pastemack M S, Klein J R, Benedetto J D, Bevan M J. Monoclonal antibodies specific for a murine cytotoxic T Iymphocyte clone. Proc Natl Acad Sci USA 1984; 81: 1799–1803
   PubMed Web of Science ®Google Scholar
• Crispe I N, Bevan M J, Staerz U D. Selective activation of Lyt-2 + precursor T cells by ligation of the antigen receptor. Nature 1985; 317: 627–629
   PubMed Web of Science ®Google Scholar
• Staerz U D, Bevan M J. Activation of resting T lymphocytes by an monoclonal antibody directed against an allotypic determinant on the T cell receptor. Eur J Immunol 1986; 16: 263–269
   PubMed Web of Science ®Google Scholar
• Staerz U D, Bevan M J. Use of anti-receptor antibodies to focus T cell activity. Immunol Today 1986; 7: 185–189
   PubMedGoogle Scholar
• Liu M A, Kranz D M, Kumick J T, Boyle L A, Levy R, Eisen H N. Heteroantibody duplexes target cells for lysis by cytotoxic T Iymphocytes. Proc Natl Acad Sci USA 1985; 82: 8648–8652
   PubMed Web of Science ®Google Scholar
• Perez P, Hoffman R W, Shaw S, Bluestone J A, Segal D M. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985; 316: 354–356
   PubMed Web of Science ®Google Scholar
• Clark M, Waldmann H. T cell killing of target cells induced by hybrid antibodies: A comparison of two bi-specific monoclonal antibodies. J Natl Cancer Inst 1987; 79: 1393–1401
   PubMed Web of Science ®Google Scholar
• Staerz U D, Yewdell J W, Bevan M J. Hybrid antibody mediated lysis of virus infected cells. Eur J lmmunol 1987; 17: 571–574
   PubMed Web of Science ®Google Scholar
• Roosnek E, Lanzvecchia A. Triggering T cells by otherwise inert hybrid anti-CD3/anti-tumor antibodies requires encounter with the specific target cell. J Exp Med 1989; 170: 297–302
   PubMed Web of Science ®Google Scholar
• Staerz U D. Targeting for lysis by CTL. Human Tumor Antigens and Specific Tumor Therapy. UCLA Symposia on Molecular and Cellular Biology, New Series, Vol 99, R. Metzgar, M. Mitchell. Alan R. Liss, New York, 209–219
   Google Scholar
• Barr I G, Miescher S, Von Fliedner V, Buchegger F, Barras C, Lanzavecchia A, Mach J P, Carrel S. In vivo localization of a bispecific antibody which targets human T lymphocytes to lyse human colon cancer cells. Int J Cancer 1989; 43: 501–507
   PubMed Web of Science ®Google Scholar
• Nitta T, Sato K, Okumura K, Ishii S. Induction of cytotoxicity in human T cells coated with anti-glioma × anti-CD3 bispecific antibody against human glioma cells. J Neurosurg 1990; 72: 476–481
   PubMed Web of Science ®Google Scholar
• Nitta T, Ishizawa A, Ito M, Sato K, Yagita H, Kumura K. Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells. No Shinkei Geka 1990; 18: 1001–1006
   PubMedGoogle Scholar
• Karpovsky B, Titus J A, Stephany D A, Segal D M. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J Exp Med 1984; 160: 1686–1701
   PubMed Web of Science ®Google Scholar
• Zepp F, Staerz U D. Hybrid antibodies induce selection processes in the thymus. Nature 1988; 336: 473–475
   PubMed Web of Science ®Google Scholar